Day 2 - Afternoon

Group 5A: HR+ Breast Cancer; Quality of Life; Older Populations Last Few Tickets

Group 5B: Metastatic Breast Cancer; Male Breast Cancer; Tumor & Immune Microenvironment

Group 5C: HER2+ Breast Cancer; Clinical Trials; Treatment De-escalation Sold Out

Group 5D: HER2-low, HER2-0, & Triple Negative Breast Cancer

Group 5E: Triple Negative Breast Cancer; Black Populations; Tumor & Immune Microenvironment

Group 5F: Lobular Breast Cancer; Predictive Biomarkers Last Few Tickets